GILD
Gilead Sciences Inc.
Price performance
Sep 18, 2026About
Company activity
29 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/04 | GILD | 8-K | Gilead Sciences Reports Q2 2026 Financial Results with Significant Acquisition-Related Expenses | — | — | — |
| 05/20 | GILD | 8-K | Gilead Sciences Announces Issuance of Senior Notes | — | — | — |
| 05/07 | GILD | 8-K | Gilead Sciences Reports Strong Q1 2026 Results and Updates Guidance | — | — | — |
| 05/04 | GILD | 8-K | Gilead Sciences Elects New Board Members and Approves Key Proposals at 2026 Annual Meeting | — | — | — |
| 04/28 | GILD | 8-K | Gilead Sciences Completes Acquisition of Arcellx | — | — | — |
| 02/23 | GILD | 8-K | Gilead Sciences to Acquire Arcellx for $7.8 Billion | — | — | — |
| 02/10 | GILD | 8-K | Gilead Sciences Reports Strong 2025 Financial Results | — | — | — |
| 11/19/25 | GILD | 8-K | Gilead Sciences Announces Departure of Executive Vice President | — | — | — |
| 10/30/25 | GILD | 8-K | Gilead Sciences Reports Q3 2025 Financial Results and Business Updates | — | — | — |
| 10/06/25 | GILD | 8-K | Gilead Sciences Settles Patent Litigation with Generic Manufacturers | — | — | — |
| 08/14/25 | GILD | 8-K | Gilead Sciences Appoints New Senior Vice President and Controller | — | — | — |
| 08/07/25 | GILD | 8-K | Gilead Sciences Reports Second Quarter 2025 Financial Results and Raises Guidance | — | — | — |
| 08/04/25 | GILD | 8-K | Gilead Sciences Updates Corporate Governance | — | — | — |
| 05/08/25 | GILD | 8-K | Gilead Sciences Reports Voting Results from 2025 Annual Meeting | — | — | — |
| 04/24/25 | GILD | 8-K | Gilead Sciences Reports Q1 2025 Financial Results | — | — | — |
| 03/12/25 | GILD | 8-K | Gilead Sciences Announces Departure of CAO and Interim Replacement | — | — | — |
| 02/11/25 | GILD | 8-K | Gilead Reports Q4 and FY 2024 Results: Revenue Up, EPS Down | — | — | — |
| 12/13/24 | GILD | 8-K | Gilead Sciences Appoints New Chief Medical Officer | — | — | — |
| 11/20/24 | GILD | 8-K | Gilead Sciences Announces Issuance of $3.5B Senior Notes | — | — | — |
| 11/06/24 | GILD | 8-K | Gilead Sciences Reports Third Quarter 2024 Financial Results | — | — | — |
| 08/08/24 | GILD | 8-K | Gilead Reports 5% Revenue Growth in Q2 2024, Reiterates Full-Year Guidance | — | — | — |
| 07/17/24 | GILD | 8-K | Gilead Sciences Announces Departure of Chief Medical Officer Merdad Parsey | — | — | — |
| 05/09/24 | GILD | 8-K | Gilead Sciences Approves Amendments and Director Elections at 2024 Annual Meeting | — | — | — |
| 04/25/24 | GILD | 8-K | Gilead Announces Q1 2024 Financial Results and Strategic Updates | — | — | — |
| 03/22/24 | GILD | 8-K | Gilead Sciences Completes Acquisition of CymaBay Therapeutics | — | — | — |
| 03/14/24 | GILD | 8-K | Gilead Sciences Director Kevin E. Lofton to Retire | — | — | — |
| 02/12/24 | GILD | 8-K | Gilead Sciences Announces Acquisition of CymaBay Therapeutics for $4.3 Billion | — | — | — |
| 02/06/24 | GILD | 8-K | Gilead Sciences Reports Q4 and Full Year 2023 Financial Results | — | — | — |
| 02/02/24 | GILD | 8-K | Gilead Sciences Appoints Ted W. Love, M.D., to Board of Directors | — | — | — |
GILD filing record
Gilead Sciences Inc. (GILD): 29 8-K filings summarized, the most recent on Aug 4, 2026.
What the 8-K filings said
- Aug 4, 2026 · low impact
Gilead Sciences, Inc. reported its financial results for the quarter ended June 30, 2026, showing a 10% increase in total revenues to $7.8 billion. Product sales excluding Veklury increased by 10% to $7.6 billion, driven by higher sales of HIV products, Trodelvy, and Livdelzi. However, the company reported a diluted…
Gilead Sciences Reports Q2 2026 Financial Results with Significant Acquisition-Related Expenses - May 20, 2026 · medium impact
On May 20, 2026, Gilead Sciences, Inc. announced the issuance of $500,000,000 aggregate principal amount of 4.250% Senior Notes due 2028, $1,000,000,000 aggregate principal amount of 4.400% Senior Notes due 2029, $1,000,000,000 aggregate principal amount of 4.600% Senior Notes due 2031, and $500,000,000 aggregate…
Gilead Sciences Announces Issuance of Senior Notes - May 7, 2026 · high impact
Gilead Sciences, Inc. announced its first quarter 2026 financial results, showing an 8% year-over-year growth in product sales excluding Veklury, driven by a 10% increase in HIV product sales and a 37% rise in Trodelvy sales. The company reported total revenues of $7.0 billion, a 4% increase from the same period in…
Gilead Sciences Reports Strong Q1 2026 Results and Updates Guidance - May 4, 2026 · medium impact
Gilead Sciences, Inc. held its 2026 annual meeting of stockholders on April 30, 2026. The meeting saw the election of nine new directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and the approval of the amended Gilead Sciences, Inc. 2022 Equity Incentive Plan.…
Gilead Sciences Elects New Board Members and Approves Key Proposals at 2026 Annual Meeting - Apr 28, 2026 · high impact
Gilead Sciences, Inc. has completed its acquisition of Arcellx, Inc. for $115 per share in cash and one contingent value right (CVR) of $5 per share, totaling approximately $7.8 billion. The acquisition provides Gilead with full control of an investigational BCMA-directed CAR T-cell therapy for multiple myeloma…
Gilead Sciences Completes Acquisition of Arcellx
SEC filings in the last five years
- 43 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 8-K/A